📰 Inducement Plan News
Page 2 - Inducement Plan News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Inducement Plan. Real-time updates on events, politics, business and more.
May 3, 2024
WALTHAM, Mass., May 3, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. , a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and...
May 3, 2024
Spyre Therapeutics, Inc. (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel...
May 3, 2024
/PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...
April 10, 2024
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigels Inducement Plan, approved...
April 2, 2024
Spyre Therapeutics, Inc. (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel...
April 2, 2024
/PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a leading...
April 1, 2024
/PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...
April 1, 2024
LAUSANNE, Switzerland, April 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (the “Company”) (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 53,800 of the Company’s common shares to six new employees on April 1, 2024 (each, a “Grant”). The Grants were offered as material inducement to the employees’ employment. The grants were approved by the Compensation Committee of the Company’s Board of Dir...
March 28, 2024
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an...
March 28, 2024
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on March 28, 2024. One individual was...